Physician profile
Buff R Greider
NPI 1811915846
$603.31
in general payments reported to CMS, 2019-2025
16 companies · $18.60 in 2025
The $18.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $103 · 2025: $18.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $158.80 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $61.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.62 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $49.00 | 2019-2020 | |
| Incyte Corporation | $36.41 | 2019 | |
| Celgene Corporation | $32.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.63 | 2019 | |
| Eisai INC. | $27.31 | 2020 | |
| Rigel Pharmaceuticals, INC. | $25.65 | 2019 | |
| Blueprint Medicines Corporation | $24.97 | 2020 | |
| Amgen INC. | $23.44 | 2019 | |
| Lilly USA, LLC | $23.05 | 2019 | |
| Abbott Laboratories | $18.60 | 2025 | Freestyle Libre 3 |
| Foundation Medicine, INC. | $15.91 | 2020 | |
| Emergent Biosolutions INC. | $15.07 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buff Greider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.